A study on the relationship between MDR1 mutation and ex vivo drug sensitivities of canine lymphomas

January 29, 2025

Abstract

The MDR1 gene encodes P-glycoprotein, a key adenosine triphosphate-dependent efflux pump involved in drug metabolism. Mutations in MDR1 can lead to altered drug transport, contributing to multi-drug resistance in canine lymphoma, which complicates treatment and affects patient survival. The objective of this study was to investigate the relationship between MDR1 mutations and ex vivo drug sensitivities in canine lymphoma patients. Using patient-derived cells from 76 dogs, we assessed cell size, granularity, antigen expression, and drug sensitivity to 12 anti-cancer agents, while also examining clinical outcomes. Our results showed that MDR1-mutated cells exhibited significantly higher ex vivo sensitivity to mitoxantrone, melphalan, and dexamethasone. Additionally, T-cell lymphomas displayed lower drug sensitivity and worse clinical outcomes compared to B-cell lymphomas. Importantly, MDR1-mutated patients demonstrated inferior survival, with a median overall survival of 74 days compared to 204 days for wild-type patients. In this manner, MDR1 mutation is a critical factor influencing drug sensitivity and clinical outcomes in canine lymphomas. Incorporating MDR1 genotyping and ex vivo drug sensitivity testing could enable more personalized and effective treatment strategies, improving both safety and efficacy for affected dogs.

Scientific Publications

Identification of novel genetic mutations for the treatment prognostication of canine lymphoma

npj Precision Oncology
Learn More →

Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers

Blood Research
Learn More →

Prognostic Utility of the Flow Cytometry and Clonality Analysis Results for Feline Lymphomas

Veterinary Sciences
Learn More →

Multimodal machine learning models identify chemotherapy drugs with prospective clinical efficacy in dogs with relapsed B-cell lymphoma

Frontiers in Oncology
Learn More →

Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia

Haematologica
Learn More →

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma

npj Precision Oncology
Learn More →

Predicting Dynamic Clinical Outcomes of the Chemotherapy for Canine Lymphoma Patients Using a Machine Learning Model

Veterinary Sciences
Learn More →

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Veterinary and Comparative Oncology
Learn More →